More on VRCA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.06 |
|
|||
| Open | $5.06 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $5.25 | ||||
| Day Low | $4.86 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 56,849 | ||||
- Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Verrica completes enrollment in YCANTH wart trial, data due Q1 2027
- Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
- Lake Street Starts Verrica Pharmaceuticals (VRCA) at Buy
- Form 4 Verrica Pharmaceuticals For: Aug 17 Filed by: Zawitz David
- Form 4 Verrica Pharmaceuticals For: Aug 14 Filed by: Rieger Jayson
- Form 4 Verrica Pharmaceuticals For: Aug 18 Filed by: Kirby John J.
- Form 4 Verrica Pharmaceuticals For: Aug 17 Filed by: Rosenberg Noah L.
- Verrica Pharmaceuticals Inc. (VRCA) Misses Q2 EPS by 8c
Entities mentioned with VRCA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
